WO1995015493A1 - Procede et systeme pour depister anonymement une maladie chez l'homme - Google Patents

Procede et systeme pour depister anonymement une maladie chez l'homme Download PDF

Info

Publication number
WO1995015493A1
WO1995015493A1 PCT/US1994/012623 US9412623W WO9515493A1 WO 1995015493 A1 WO1995015493 A1 WO 1995015493A1 US 9412623 W US9412623 W US 9412623W WO 9515493 A1 WO9515493 A1 WO 9515493A1
Authority
WO
WIPO (PCT)
Prior art keywords
person
test
personal code
specimen
tested
Prior art date
Application number
PCT/US1994/012623
Other languages
English (en)
Inventor
Richard A. Quattrocchi
Original Assignee
Anonymous Test Services, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anonymous Test Services, Inc. filed Critical Anonymous Test Services, Inc.
Priority to AU81318/94A priority Critical patent/AU8131894A/en
Publication of WO1995015493A1 publication Critical patent/WO1995015493A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/54—Labware with identification means
    • B01L3/545—Labware with identification means for laboratory containers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Definitions

  • the present invention relates to a method and system for testing for human malady and, more pa ⁇ icularly, to a method and system for testing for the Human Immunodeficiency Virus (HIV) which is responsible for Acquired Immune Deficiency Syndrome (AIDS).
  • HIV Human Immunodeficiency Virus
  • AIDS Acquired Immune Deficiency Syndrome
  • AIDS has become a serious health threat and has reached epidemic proportions around the world.
  • HIV virus does not necessarily mean that a person will contract AIDS, because of its contagiousness and transmissibility, it is important to know whether a person is infected with the HTV virus.
  • HTV and AIDS are not inherited but are acquired. HIV is passed from one person to another as through the transference body fluid such as infected blood, semen or vaginal fluids. Accordingly, HTV is often transmitted by unprotected vaginal, anal, or oral sexual intercourse, or through the sharing of hypodermic needles by intravenous drug users. Infants can also acquire HIV from their mothers during pregnancy or delivery.
  • a fundamental step in preventing the spread of HIV and AIDS is to inform those people who are infected about their condition. Hopefully, once someone knows they are O 95/15493
  • test results can be approximately 99.7 percent accurate.
  • HIV antibodies develop in the blood stream after someone is infected with HIV. These antibodies can take up to six (6) months to develop before being detected by d e ELISA and Western Blot tests. Accordingly, immediate infection with HIV virus is not necessarily detectable.
  • Tests have been developed and marketed that allow people to take a blood sample at home and mail it to a medical laboratory for analysis, e.g., Briggs et al. United States Patent Nos. 4,777,964 and 4,979,515. These tests offer anonymity because the user does not appear at a laboratory, hospital or doctor's office. These tests, however, do require the person taking the test to give the laboratory his or her name and address. Thus, total anonymity for the person being tested is lost thereby discouraging people from taking the test.
  • the previous personal testing kits have only required the user to supply one blood sample. While often this is sufficient for accurate results, sometimes more than one blood sample is required because multiple tests are needed. It is important to make sure that the results to HIV antibody tests are accurate because of the severe consequences, e.g. death and discrimination, of a positive result.
  • a medical testing system is needed that is particularly designed to test for the HIV virus and allow the user to be completely anonymous.
  • the test should also supply the medical lab with enough blood samples to ensure that the test result is as accurate as possible.
  • the presently described invention addresses these mentioned needs.
  • a method and system of testing for a human malady in private One such human malady would be HIV.
  • the test is privately conducted and d e test results are anonymously reported to the person taking the test without revealing his or her identity.
  • the method includes the steps of procuring a kit that is capable of taking a suitable test specimen from the person being tested.
  • the kit has a unique personal code associated with it and all the necessary equipment for the person taking the test to be able to obtain the test specimen in private.
  • the person taking the test proceeds by creating or activating a personal electronic file through a telephone operated software program.
  • the electronic file that is set up is identified by the personal code assigned to the kit.
  • the electronic file is a data file for demographic information about the individual.
  • the person taking the test can also be offered pretest counseling regarding the test and the test results.
  • the method continues with the person taking the test using the equipment provided in the kit to obtain the test specimen.
  • the person taking the test is
  • test specimen is a blood sample.
  • the next step is sending the test specimen for analyzation; the test specimen is sent with only the personal code to identify the person taking the test.
  • the next step is analyzing the sample to obtain results.
  • the person taking the test is concerned about HIV
  • the ELISA and Western Blot methods to determine if the HIV antibodies are present in the test specimen.
  • Other tests can be performed on the test specimen to detect a variety of diseases.
  • d e electronic file identified by the personal code that corresponds to the personal code of d e test specimen is updated by adding d e results.
  • the next step is telephonically accessing die test results in the personal electronic file through the telephone operated software program using the personal code, thereby maintaining anonymity.
  • the telephone operated software proceeds by sending the person to d e appropriate source to receive d e results. If the test results show the presence of a human malady, die person taking die test is told the results and counseled by a counselor who does not know die identity of the person. On the other hand, if the test results show no human malady, die individual is told by the telephone
  • the test system herein permits anonymous testing for a particular human malady
  • die system includes a kit having die necessary equipment for producing a suitable test specimen from a person being tested which is capable of being transported from one location to another location for analyzation.
  • the kit allows the specimen to be collected in private.
  • a personal code identifies d e person being tested and the test specimen.
  • An electronic file is created and accessible by die person being tested and is identified by die same personal code. The electronic file has entered into it the results of the analysis after the test specimen is analyzed.
  • d e test kit is equipped wid all d e proper equipment that an individual will need to acquire a test specimen.
  • the equipment will obtain a blood sample mat is sufficient to analyze for HIV antibodies using the ELISA med od and die Western Blot method.
  • the kit comes equipped widi an alcohol swab to clean an area of the skin, preferable the tip of die middle or ring finger, before the blood sample is taken, and at least two lancets diat can puncture the skin so that blood can be acquired.
  • a sterile gauze pad is provided to clean away the first drop of blood which is not suitable for the blood sample.
  • the blood sample is produced by placing enough blood on a specially designed blood specimen collection card provided in the kit to fill preferably four specimen spots.
  • the collection card is preferably configured as a iree part card.
  • the first part of the card has printed thereon the personal code and a telephone number that is used by d e person being tested to create the personal electronic file.
  • the second part is an informed consent form with an area to be anonymously filled in by the person being tested widi the personal code.
  • the d ird part is special paper with specimen spots outlined d ereon for the person being tested to create specimens for testing.
  • the test kit further includes at least one bandage to protect the puncture after the blood sample is produced.
  • die kit is supplied with a foil lined envelope
  • the individual inserts the collection card and a drying agent.
  • the foiled lined envelope is placed in a specially marked specimen bag mat is also sealed.
  • the waste is placed in another specially marked waste bag that is also sealed.
  • the specimen bag and the waste bag are placed in a container, which is then placed in a mailing envelope and sent for analyzation and disposal, respectively.
  • die waste can be disposed of locally.
  • FIGURE 1 depicts d e outer box that holds d e contents of the medical testing equipment of the presently disclosed invention:
  • FIGURE 2 illustrates the box of FIGURE 1 in its open state with an exploded view of the testing equipment
  • FIGURE 3 illustrates the sealed bag and die enclosed equipment in block form of the present invention
  • FIGURE 4A & 4B are detailed drawings of the blood specimen collection card
  • FIGURE 5 is a flow chart showing the steps a user takes to obtain a blood specimen
  • FIGURE 6 A & 6B illustrate the elements of the electronic file
  • FIGURE 7 is a flow chart showing die operation of the telephone operated automated software associated widi die present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • kit 10 includes an outer box 12 used to package and mail die kit 10. Multiple tabs 14 inserted into multiple slots 16 are provided to keep die box 12 in its folded and secure position as shown in FIGURE 1.
  • FIGURE 2 illustrates how when tabs 14 are removed from slots 16 box 12 can be unfolded to reveal the enclosed equipment which are used for die anonymous medical test. All equipment in the medical test comes confined in a vacuum sealed clear plastic bag 18 as shown in FIGURE 3. The clear plastic bag allows the person being tested to examine the contents of the test to determine if all the necessary parts are provided.
  • the necessary components for the test are also revealed in FIGURES 2 and 3.
  • the equipment preferably includes: 1) an alcohol swab 20; 2) at least two lancets 22; 3) a gauze pad 24; 4) a blood specimen collection card 26; 5) at least two bandages 28; 6) a drying agent (desiccant) 30; 7) a storage packet 32; 8) a specimen bag 34, and 9) a waste bag 36.
  • a mailing envelope 38 may also be provided widi die kit 10 to facilitate
  • Alcohol swab 20 is preferably a 1 1/4 inch by 2 5/8 inch single fold, nonwoven applicator swab saturated widi 70% isopropyl alcohol. To prolong the usefulness, swab 20 is preferably packaged in a foil tear-open packet, and can be of die type produced by Baxter Healdicare Corporation. Alcohol swab 20 is used to clean an area of skin from which blood will be drawn.
  • Lancets 22 are preferably single use lancets widi a blade widd of 1.0 mm and blade depth of 2.2 mm such as Becton Dickinson Microtainer Brand "Yellow" Safety Flow Lancets. Lancets 22 are used to puncture the cleaned skin of the user.
  • Gauze pad 24 is preferably a 2 inch by 2 inch sterile 12-ply sponge pad of 100% cotton USP Type VII gauze like that manufactured by Johnson & Johnson. Gauze pad 24 is used to clean and dry the skin around the puncture area.
  • the bandages 28 provided are preferably 1 inch by 3 inch sterile wrapped adhesive strips of the type manufactured by Johnson & Johnson as Band- Aid ® brand bandages.
  • the bandages 28 are used to cover the punctured skin after blood samples are taken.
  • the drying agent 30 can be any desiccant, but is preferably a silica gel like the one produced by U.D.G of Belen, New Mexico and marketed as Sorb-It ® .
  • FIGURES 4A and 4B illustrates the blood specimen collection card 26 which is preferably a 4 1/2 inch by 3 1/2 inch diagnostic form having three (3) parts.
  • the first part is a removable top sheet 40.
  • Perforations 42 are preferably provided to enable die person being tested to remove the top sheet 40 from the remainder of the collection card 26.
  • Printed on top sheet 40 is information that the person being tested needs to retain after the remainder of the collection card is sent for analysis. This information includes a personal code 44 and a phone number 46.
  • Personal code 44 is used to identify die blood specimen and d e person being tested rather than a name and/or address.
  • the personal code 44 is a randomly assigned number to the kit 10 so diat each kit has a unique code 44 associated dierewith. Because each number is unique, the person being tested can remain completely anonymous while having his or her blood specimen analyzed.
  • the personal code 44 is preferably an eleven (11) digit number. Nine digits, indicated by "0"s, are randomly assigned and the remaining two digits, indicated by "X"s, are used as a check sum to assure accuracy each time the number is used. It should be noted that any odier system of identification can be used as long as d e indicators are randomly assigned to each kit 10.
  • the telephone number 46 allows the user to access the telephone operated software program 48 to generate a personal electronic file 50 and to access the results of the test, which will be discussed below.
  • the second part of collection card 26 is an informed consent form 52.
  • the informed consent form 52 contains a series of statements that the person being tested must read, understand, and acknowledge before a laboratory can perform any test on the specimen.
  • the informed consent form 52 is returned along widi die specimen.
  • the consent form 52 has a space 54 which the individual fills in thereby acknowledging having read and understood die statements. To keep the anonymity of me person being tested, the user fills in the space 54 widi die personal code 44.
  • sample sheet 56 is made of at least in part a cotton fiber filter paper preferably like that manufactured by Schleicher and Schuell ® as #903TM. Sample sheet 56 has similarly shaped
  • sections 58 outlined d ereon. In the preferred embodiment, four sections 58 are used so that d e individual will provide at least four specimens for analyzation.
  • the sections 58 are outlined using black biological ink so that die ink will not interfere with the specimen and an accurate test result can be obtained. It is best if die shapes are circles of approximately 0.375 inches in diameter.
  • the sections 58 are spaced adequately apart so that die four different specimens will not be commingled and diat acquiring the specimens will not be too difficult.
  • Also placed on die sample sheet is a bar code 60 that has die same personal code 44 as was randomly assigned to die top sheet 40. The bar code 60 is used by the laboratory to identify die specimen as belonging to die person being tested who has been assigned die corresponding personal code 44. Accordingly, d e person being tested and assigned d e personal code 44 can be updated widi die results of the analyzation.
  • Storage packet 32 is opaque and is preferably a foil lined envelope. As shown in FIGURE 2, the top edge 62 has an adhesive strip 64 covered by removable silicon strip. The dimensions of storage packet 32 are large enough to hold the collection card 26. After the test specimen has been completed, it is inserted widiin the storage packet 32 along with d e drying agent 30.
  • Specimen bag 34 is a clear plastic bag that can be securely sealed along its upper edge and is large enough to hold die storage packet 32.
  • Specimen bag 34 On the outside surface of the specimen bag 34, there is a label 66 preferably stating "specimen" so mat d e purpose and contents of die bag are clearly stated.
  • the waste bag 36 is also a clear plastic bag that can be securely sealed along its upper edge.
  • Waste bag 36 also preferably has a label 68 stating "Caution Biohazard" along with d e typical biohazard symbol so mat die contents of the bag 36 are readily identified as medical waste.
  • the waste bag is large enough to hold the remaining and used elements of the test system 10, e.g. me lancets 22 and gauze 24.
  • Mailing envelope 38 is preferably a typical express mail type envelope used by e.g. , Federal Express ® or the United States Postal Service. ® The mailing envelope 38 should be sufficiently large enough to hold die box 12 dierein for sending to die laboratory.
  • FIGURE 5 illustrates the use of die kit 10 and d e equipment described above.
  • the user opens up the box to reveal the testing equipment (See FIGURES 1 and 2).
  • the kit 10 can also contain an instruction booklet (not shown) which serves to help the person being tested obtain a specimen and answer any questions.
  • the person being tested should activate the personal code 44 assigned to the kit 10 using the telephone automated software program 48.
  • the user will find die assigned code 44 on die top sheet 40 of the collection card 26.
  • the telephone number 46 the person being tested calls to activate die personal code 44.
  • die user registers the code 44 at a central location. If the user does not have a touch tone telephone, a counselor will be provided to activate the personal code 44.
  • telephone automated software program 48 collects demographic information, and the
  • the demographic information will not include any information that would divulge die true identity of die person being tested.
  • the type of information sought concerns the sex and age of die person being tested, and the person's zip code and is inserted into a database electronic file 50 as depicted in FIGURE 6.
  • Organizations like a local health department the Center for Disease Control in Atlanta, Georgia can then use diis information for statistical purposes in its monitoring of the AIDS epidemic.
  • the pre-test counseling is an opportunity for the central location to help the person being tested cope widi die possibility diat d e results from the test will be positive.
  • a counselor will ask a series of questions like, "What do you expect your test results to be?” "What would you do if your test results are positive?" "Who could you rely on for support if your test results are positive?” etc.
  • the person being tested must also acknowledge that he or she has read and understood the informed consent form 52 on the collection card 26.
  • the informed consent form 52 has a series of statements informing the user about the test, the meaning of the results, and audiorizing a medical laboratory to test the blood specimen sent to it for the presence of HIV antibodies. In order to protect anonymity, the person being tested is reminded to fill in die consent form 52 with the assigned personal code 44 rather than sign his or her name. The consent form 52 should not be removed from the collection card 26.
  • the person being tested dien selects and cleans a skin area with soap and water.
  • die alcohol swab 20 is preferably used to further clean an area.
  • the skin area can be from any part of the body, but d e tip of the middle or ring finger is preferable. After the fmger is cleaned, d e person being tested should dry the finger tip with die sterile gauze pad 24.
  • the person being tested opens one of d e two lancets 22 provided which will be used to puncture die cleaned area thereby producing a flow of blood.
  • die person being tested should stabilize the finger such as on a flat hard surface and position die lancet 22 between die fore and middle fingers of the opposite hand.
  • the lancet 22 is dien placed against the pad of d e finger tip thereby causing a dimple.
  • die lancet's plunger is depressed and held for a split-second. This motion causes die blade of die lancet to puncture the skin thereby producing a flow of blood.
  • die lancet is removed from the finger area, and die first drop of blood is wiped away by die sterile gauze pad 24. Anodier drop of blood should develop soon diereafter.
  • the person being tested applies die drops of blood developing on d e finger tip to the sample sheet 56 of the collection card 26 by gently touching the finger to each of the separate specimen sections 58 after a large drop of blood has developed.
  • the person being tested should keep die sample sheet 56 in contact with die finger to allow a sufficient quantity of blood to soak dirough sample sheet 56 and fill die specimen sections 58.
  • Each of the specimen sections 58 provided should be filled in a similar fashion.
  • die person can use another lancet 22 to create a second puncture area on the finger thereby causing blood to flow from a different spot.
  • lancets 22 are designed for single use and attempting to use a lancet 22 twice might not produce a flow of blood.
  • the collection card 26 and waste is preferably prepared for sending away where they will be analyzed and disposed of, respectively. Alternately, the waste can be disposed of locally.
  • the drying agent 30 is inserted into the storage packet 32 and followed by d e collection card 26.
  • the silicon strip is removed, and die top edge 62 of die storage package 32 is folded over so that the adhesive strip 64 sticks to the outside surface of the storage packet 32 thereby sealing the collection card into the storage bag 32.
  • die person being tested inserts it into the specimen bag 34, which is sealed at its top edge. The person being tested then places the remaining equipment into the waste bag 36.
  • the items to be placed into the waste bag 36 preferably include the used alcohol
  • the person being tested dien takes the specimen bag 34 and the waste bag 36 and puts diem into die box 12.
  • the flaps 14 are inserted into the slots 16 so that die box is secured shut.
  • the person places the box 14 into the mailing envelope 38 so diat die medical lab can receive the collection card 26 and the waste for testing and disposal, respectively.
  • the user should wait a number of days before analysis can be performed on die specimen and the results relayed to die user.
  • the laboratory receives the collection card 26, it will perform the ELISA test to detect for HIV antibodies. If die ELISA test is positive, die Western Blot test will be performed to confirm a positive result.
  • die laboratory will update die electronic file 50 set up by the person being tested diat corresponds to die bar code 60. After the electronic file 50 is updated, die person can access the test results. It should take approximately seventy-two hours after die laboratory has received die collection card 26 to update the electronic file 50.
  • the person will call the phone number 46, which can be found on the retained top sheet 40. If the test results are negative, the telephone- operated computer software program 48 will so inform the user. On the other hand, a counselor will inform me user of the positive results. This way the user can be told how to get the proper medical attention and to determine if the user has possibly infected others with the HIV virus. At no point in the process is the identity of the user revealed. Also if die test results are positive, the local heald department and/or the Center for Disease Control can be informed.
  • FIGURE 6A & 6B illustrates the elements of the personal electronic file 50 that is created by the person being tested when he or she telephones the telephone automated computer program 48 to activate the personal code 44 assigned to d e kit 10.
  • the electronic file 50 is a computer database file d at holds all d e relevant non-identifying data about die person being tested.
  • the electronic file 50 has at least two area; a patient record 70 and a call log 72.
  • the patient record holds relevant information about the person such as the personal code 44, the sex, birth date, zip code, whedier the person has been tested before, and test result.
  • a call log 72 is set up for each time mat die user calls. Each call log 72 is identified by the users personal code 44, and also designates die date and time of each call. There is also space for a counselor to put notes about each call.
  • the telephone automated software program 48 has been developed for people to set up and access ti eir electronic files 60. When a person calls the telephone number 46, the person first accesses the telephone automated software program 48.
  • FIGURE 7 is a flow chart illustrated die steps of the telephone automated software program 48.
  • the program 48 preferably begins by asking if the user is calling to set up his or her electronic file 50, or calling to receive test results. (Step 1). The person being tested selects the appropriate number on the push button telephone depending on the response to step one. If die person does not have a touch tone telephone, a counselor will answer the phone and proceed in collecting the relevant information.
  • the program 48 asks die user to enter the eleven digit personal code 44. (Step 2). After the number is entered, die program 48 repeats the entered number. (Step 3). If the number repeated is incorrect, Step 2 is repeated, odierwise the program 48 proceeds by asking die person to complete the electronic file 50. (Step 4). After the electronic file 50 is completed, me program 48 connects the user to a counselor for pre-test counseling. (Step 5).
  • the program 48 begins by asking the person to enter the eleven digit personal code 44. (Step 6). After the number is entered, die program 48 repeats the entered number. (Step 7). If the number repeated is incorrect, Step 6 is repeated, odierwise the program 48 proceeds so diat the person will receive the test result. If the test results are negative, the program 48 so informs the person. (Step 8). Step 8 also encourages the user to talk to a counselor and to take the test again if there is any reason to believe that HIV antibodies will develop in die future. (Step 9)
  • Step 10 further takes the opportunity to counsel the person being tested about how to get proper medical attention, face-to-face counseling and to determine if mere are any people that die user should inform about the test results because they might also be infected widi die HIV virus.

Abstract

Système de dépistage anonyme, permettant de prélever en privé un échantillon d'un fluide organique à soumettre à l'essai, de l'envoyer pour être analysé et d'obtenir les résultats de l'analyse. Ce système comprend un kit d'essai permettant de prélever un échantillon de fluide organique, un code personnel permettant d'identifier anonymement l'échantillon et la personne concernée, ainsi qu'un fichier électronique créé par téléphone et auquel la personne subissant le dépistage et identifiée par le code personnel a accès. Le fichier électronique contient les résultats de l'analyse. L'invention se rapporte également à un procédé de dépistage anonyme et privé consistant à soumettre à un essai un fluide organique d'une personne, la personne pouvant recevoir les résultats de manière anonyme sans être appelée à révéler son identité. Ce procédé consiste à produire un kit d'essai permettant de prélever un échantillon du fluide organique. Le kit comprend un code personnel associé, ainsi que des instruments permettant de prélever l'échantillon. La personne utilise les instruments pour prélever l'échantillon et expédie ce dernier avec le code personnel à un site d'essai. La personne crée également un fichier électronique personnel par téléphone; ce fichier est identifié par le code personnel. L'échantillon est également identifié par le code personnel. Au niveau du site d'essai, l'échantillon est soumis à l'essai et les résultats sont mis à jour dans le fichier électronique avec un code personnel correspondant. La personne obtient ultérieurement l'accès au fichier électronique par téléphone afin d'obtenir ses résultats.
PCT/US1994/012623 1993-11-02 1994-11-02 Procede et systeme pour depister anonymement une maladie chez l'homme WO1995015493A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU81318/94A AU8131894A (en) 1993-11-02 1994-11-02 Method and system for anonymously testing for a human malady

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14630793A 1993-11-02 1993-11-02
US08/146,307 1993-11-02

Publications (1)

Publication Number Publication Date
WO1995015493A1 true WO1995015493A1 (fr) 1995-06-08

Family

ID=22516783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012623 WO1995015493A1 (fr) 1993-11-02 1994-11-02 Procede et systeme pour depister anonymement une maladie chez l'homme

Country Status (2)

Country Link
AU (1) AU8131894A (fr)
WO (1) WO1995015493A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070023A1 (fr) * 2000-02-25 2001-09-27 Jan Jaap Nietfeld Procede d'enregistrement, de memorisation et d'utilisation anonyme de materiau anatomique et/ou d'information derivee de ce materiau
WO2003063048A2 (fr) * 2002-01-22 2003-07-31 Genonyme Gmbh Procede et systeme pour l'analyse de donnees medicales et personnelles
US6867016B1 (en) * 1997-03-31 2005-03-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the gastrointestinal tract
WO2015183150A1 (fr) * 2014-05-30 2015-12-03 Bodymarkers Ab Procédé et système pour effectuer un test de santé
WO2016007064A1 (fr) * 2014-07-08 2016-01-14 Bodymarkers Ab Procédé et système d'administration d'un test de santé à un animal
US9352863B1 (en) 2007-09-18 2016-05-31 Luce Communications Llc System and method for shipping an item
US11688492B1 (en) 2018-11-27 2023-06-27 Luce Communications Llc Method and system for automated population outreach

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883396A (en) * 1973-03-30 1975-05-13 Jr Charles A Thomas Gonorrhea detecting
US4277249A (en) * 1979-10-15 1981-07-07 Nichols Institute Mammalian Somatomedin measurement
US4777964A (en) * 1986-01-02 1988-10-18 David Briggs System for obtaining blood samples and submitting for testing of aids
US4792968A (en) * 1985-07-10 1988-12-20 Fdr Interactive Technologies Statistical analysis system for use with public communication facility
US5156948A (en) * 1990-07-20 1992-10-20 Christensen Dale A Method and kit for diagnosis of diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883396A (en) * 1973-03-30 1975-05-13 Jr Charles A Thomas Gonorrhea detecting
US4277249A (en) * 1979-10-15 1981-07-07 Nichols Institute Mammalian Somatomedin measurement
US4792968A (en) * 1985-07-10 1988-12-20 Fdr Interactive Technologies Statistical analysis system for use with public communication facility
US4777964A (en) * 1986-01-02 1988-10-18 David Briggs System for obtaining blood samples and submitting for testing of aids
US5156948A (en) * 1990-07-20 1992-10-20 Christensen Dale A Method and kit for diagnosis of diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF HOSPITAL PHARMACY, Volume 47, Number 3, issued March 1990, DECHRISTOFORO, "What is the Status of AIDS Antibody Home Test Kits?", page 619. *
NATURE, Volume 332, issued 14 April 1988, ANDERSON, "Home Test Kits for AIDS Blocked", page 573. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867016B1 (en) * 1997-03-31 2005-03-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the gastrointestinal tract
WO2001070023A1 (fr) * 2000-02-25 2001-09-27 Jan Jaap Nietfeld Procede d'enregistrement, de memorisation et d'utilisation anonyme de materiau anatomique et/ou d'information derivee de ce materiau
US7706983B2 (en) 2000-02-25 2010-04-27 Intresco B.V. Method for anonymously registering, storing and using body material and/or information derived therefrom
WO2003063048A2 (fr) * 2002-01-22 2003-07-31 Genonyme Gmbh Procede et systeme pour l'analyse de donnees medicales et personnelles
WO2003063048A3 (fr) * 2002-01-22 2004-11-18 Genonyme Gmbh Procede et systeme pour l'analyse de donnees medicales et personnelles
US9352863B1 (en) 2007-09-18 2016-05-31 Luce Communications Llc System and method for shipping an item
WO2015183150A1 (fr) * 2014-05-30 2015-12-03 Bodymarkers Ab Procédé et système pour effectuer un test de santé
WO2016007064A1 (fr) * 2014-07-08 2016-01-14 Bodymarkers Ab Procédé et système d'administration d'un test de santé à un animal
US11688492B1 (en) 2018-11-27 2023-06-27 Luce Communications Llc Method and system for automated population outreach

Also Published As

Publication number Publication date
AU8131894A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
US6014438A (en) Method and system for anonymously testing for a human malady
US4777964A (en) System for obtaining blood samples and submitting for testing of aids
US5876926A (en) Method, apparatus and system for verification of human medical data
Rewri et al. Seroprevalence, risk associations, and cost analysis of screening for viral infections among patients of cataract surgery
WO1995015493A1 (fr) Procede et systeme pour depister anonymement une maladie chez l'homme
CZ327595A3 (en) Apparatus and set for sampling blood
Lindsay A protocol for routine voluntary antepartum human immunodeficiency virus antibody screening
Mejta et al. Acquired immunodeficiency syndrome (AIDS): A survey of substance abuse clinic directors' and counselors' perceived knowledge, attitudes and reactions
Scheer et al. Undiagnosed and unreported AIDS deaths: results from the San Francisco Medical Examiner
Danila et al. HIV-1 counseling and testing sites, Minnesota: analysis of trends in client characteristics.
Essien et al. Cross-national HIV infection control practices and fear of AIDS: A comparison between Nigeria and the USA
Incardona et al. Accuracy, ease of use, safety, and acceptability of a 23-μL conical cup blood transfer device for use with rapid diagnostic tests
Paul et al. Rapid diagnostic testing for HIV: clinical implications
World Health Organization Sexually transmitted infections prevalence study methodology: guidelines for the implementation of STI prevalence surveys 1999
Bsc Addis Ab College of School of All Department of Med
Blanchet Effective HIV testing strategies for chemical dependency programs
Garrels Laboratory Testing for Ambulatory Settings-E-Book: A Guide for Health Care Professionals
Karpen There's No Place Like Home: The Controversy Surrounding Home HIV Testing Kits
Sylvester et al. Demographic and Serum Alanine Aminotransferase level of Primary Health Care Workers Positive for Hepatitis B Surface Antigen and Hepatitis C Virus in Cross River North, Nigeria
Hoffmann et al. Status of serological testing for congenital syphilis
World Health Organization et al. Guidelines for using HIV testing technologies in surveillance: selection, evaluation and implementation–2009 update
Walsh HPV infection, 3 suggesting that there
Schwartländer et al. Guidelines for designing rapid assessment surveys of HIV seroprevalence among hospitalized patients. Centers for Disease Control and Prevention.
KR20020052766A (ko) 텔레커뮤니케이션 시스템을 이용한 질병의 원격진단방법
Su Guidelines for Using HIV Testing Technologies in Surveillance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP KP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA